Daito Pharmaceutical Co.,Ltd.
Symbool: 4577.T
JPX
2540
JPYMarktprijs vandaag
12.0844
Koers/Winst Verhouding
-0.4769
Koers/Winst Groei Verhouding
39.73B
MRK Kapitalisatie
- 0.02%
DIV Rendement
Daito Pharmaceutical Co.,Ltd. (4577-T) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3607 | 4381 | 3372.9 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | -205 | -206 | -294.2 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 10670 | 10585 | 8382 | |||||||||||||||
balance-sheet.row.inventory | 0 | 18238 | 16820 | 15751.7 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 8148 | 6123 | 4923.3 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 40663 | 37909 | 32429.9 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 25837 | 23116 | 21372 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 377 | 386 | 332.7 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 377 | 386 | 332.7 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 3169 | 2958 | 3096 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 504 | 570 | 508 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | -1 | 0.7 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 29887 | 27029 | 25309.5 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 2 | 1 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 70552 | 64939 | 57739.4 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 4435 | 4493 | 4359.6 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 1513 | 1200 | 1375.1 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 559 | 1402 | 1098.5 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 3445 | 2247 | 2018.9 | |||||||||||||||
Deferred Revenue Non Current | 0 | 507 | 755 | 764.3 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 4101 | 3887 | 3399.9 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 4153 | 3199 | 2963.2 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 92 | 0 | 1.5 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 19581 | 17268 | 15822 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 49141 | 46273 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 7186 | 7031 | 6271.2 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | 35006 | 32338 | 28331.6 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 1531 | 1031 | 872.4 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | -42192 | -39369 | 6143.7 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 50672 | 47304 | 41619 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 70552 | 64939 | 57739.4 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 299 | 367 | 298.4 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 50971 | 47671 | 41917.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 2964 | 2752 | 2801.8 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 4958 | 3447 | 3394 | |||||||||||||||
balance-sheet.row.net-debt | 0 | 1351 | -934 | 21.1 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 5076 | 6720 | 5873.9 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 3870 | 3313 | 3154.3 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -2326 | -4399 | -1582.4 | |||||||||||||||
cash-flows.row.account-receivables | 0 | -1502 | -3299 | 2723 | |||||||||||||||
cash-flows.row.inventory | 0 | -1413 | -1041 | -3609.2 | |||||||||||||||
cash-flows.row.account-payables | 0 | 538 | 22 | -765.1 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 51 | -81 | 69 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -2465 | -1264 | -2263.3 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -5556 | -4733 | -6349.6 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 68 | 0 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -68 | 0 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 256 | 5 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | -10 | 77 | 20.3 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -5566 | -4400 | -6324.3 | |||||||||||||||
cash-flows.row.debt-repayment | 0 | -1638 | -1444 | -1712.4 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 308 | 1514 | 1798.5 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -116 | 1499 | -0.3 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | -931 | -660 | -658.1 | |||||||||||||||
cash-flows.row.other-financing-activites | 0 | 2993 | 80 | 1997 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 616 | 989 | 1424.8 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 20 | 48 | 5.8 | |||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -774 | 1009 | 288.8 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 3607 | 4381 | 3372.9 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 4381 | 3372 | 3084.1 | |||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 4155 | 4370 | 5182.5 | |||||||||||||||
cash-flows.row.capital-expenditure | 0 | -5556 | -4733 | -6349.6 | |||||||||||||||
cash-flows.row.free-cash-flow | 0 | -1401 | -363 | -1167 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 45101 | 43464 | 48709.2 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 34770 | 32005 | 37917.3 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 10331 | 11459 | 10791.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | 3 | 37 | 28.4 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 5123 | 4905 | 4883.1 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 39893 | 36910 | 42800.3 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 45 | 46 | 0.4 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 12 | 9 | 7.8 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -135 | 152 | -43 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 3 | 37 | 28.4 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -135 | 152 | -43 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 12 | 9 | 7.8 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 3870 | 3313 | 3154.3 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | 5207 | 6553 | 5908.8 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | 5076 | 6720 | 5873.9 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 1549 | 2092 | 1716.9 | |||||||||||||||
income-statement-row.row.net-income | 0 | 3600 | 4668 | 4246 |
Vaak gestelde vragen
Wat is Daito Pharmaceutical Co.,Ltd. (4577.T) totale activa?
Daito Pharmaceutical Co.,Ltd. (4577.T) totale activa is 70552000000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.214.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.073.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.093.
Wat is Daito Pharmaceutical Co.,Ltd. (4577.T) nettowinst (netto-inkomen)?
De nettowinst is 3600000000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 4958000000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 5123000000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.